JBS N.V. (JBS) SEC Filings & Earnings Calls
EquiReason read 26 JBS N.V. SEC filings in the last 12 months. Latest: 8-K on 2026-09-15 — JBS N.V. filed an 8-K with only Item 9.01 (financial statements and exhibits) and no substantive Item 8.01 disclosure. The filing contains only a cover page exhibit. No material ev.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 13.8B
- P/E TTM
- 11.6
- Dividend yield
- 7.5%
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
19 Aug 20268-K · 7.01, 8.01JBS N.V. proposes to acquire remaining ~18% of Pilgrim's Pride shares not already owned, offering 2.086 JBS shares per PPC share. Transaction subject to special committee and unaffiliated shareholder approval.acquisitionopen
Figures in the filing · each found in the filing text
| Exchange ratio · Q3-2026 | $2.09 | |
| JBS closing share price · August 18, 2026 | $13.66 | |
| PPC closing share price · August 18, 2026 | $28.49 |
Risks flagged
Transaction subject to approval by special committee and unaffiliated shareholders; may not close.
“Subject to approval of independent special committee of PPC board and majority of unaffiliated PPC shares; non-binding proposal”
11 Aug 20268-K · 2.02, 5.02, 7.01Net Sales $23.90B (+14% y/y); Adjusted EBITDA (IFRS) $1.43B (-18% y/y); Net Income Attributable to JBS $-102Mearningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $23.90B | +14% y/y |
| Adjusted EBITDA (IFRS) · Q2-2026 | $1.43B | -18% y/y |
| Net Income Attributable to JBS · Q2-2026 | $-102M | |
| Earnings Per Share · Q2-2026 | $-0.10 | |
| Leverage (Net Debt / Adjusted EBITDA LTM) · Q2-2026 | $3.10 |
Risks flagged
Cattle supply constraints in US due to restricted Mexican imports and low cattle availability.
“Live cattle imports from Mexico remained restricted during the quarter, further constraining supply in the U.S. market.” · word for word
Antitrust settlements and tender offer costs impacting net income.
“antitrust settlements of $133 million... $172 million in premiums, interest, and costs associated with the tender offers”
Leverage above long-term target at 3.1x.
“Leverage ended 2Q26 at 3.1x, slightly above the Company’s long-term target.” · word for word
10 Aug 202610-QH1 2026 net income fell 87.4% YoY due to record cattle costs, margin compression, and higher finance expenses.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · H1-2026 | $45.51B | +12% y/y |
| Net income · H1-2026 | $145M | -87% y/y |
| Gross profit · H1-2026 | $4.91B | -10% y/y |
| Adjusted EBITDA · H1-2026 | $2.56B | -22% y/y |
| Total outstanding indebtedness · 2026-06-30 | $22.65B | |
| Cash and cash equivalents, margin cash and long-term investments · 2026-06-30 | $3.69B | |
| Revolving credit facility capacity · 2026-06-30 | $3.40B |
Risks flagged
Record cattle costs
“primarily due to the increase in the cost of cattle, which reached record levels.” · word for word
High leverage and rising interest expense
“Interest expense increased by US$205.5 million, or 25.9%, in the six-month period ended June 30, 2026” · word for word
DOJ and antitrust agreement costs
“U.S. Department of Justice and antitrust agreements increased by US$23.7 million, to US$157.4 million” · word for word
7 Aug 20266-KIndonesia sovereign fund DIM to invest USD 2.5B for 25% stake in JBS's Australia/New Zealand protein business joint venture; total capital raise up to USD 5B including debt.being acquiredopen
Figures in the filing · each found in the filing text
| DIM Investment | $2.50B | |
| Total Capital Raise | $5.00B |
Risks flagged
Transaction subject to regulatory approvals and closing conditions; may not occur as planned.
“Completion remains subject to regulatory approvals and other customary closing conditions.”
Exchange right for DIM to convert JV stake into JBS shares could dilute existing shareholders.
“DIM has the right to exchange its JV shares for newly issued JBS shares after 6 years if no IPO.”
5 Aug 20266-KJBS N.V. upsized global revolving credit facility to $2.65B, expanding total availability to $4.2B; strengthens liquidity position.open
Figures in the filing · each found in the filing text
| Revolving credit facility amount | $2.65B | |
| Total revolver capacity | $4.20B |
12 May 20266-KJBS N.V. filed Q1 2026 results with net revenue $21.6B, operating profit $484M, net income $242M; revenue up 10.7% YoY but profit down 45% due to cost pressures.open
Figures in the filing · each found in the filing text
| Net Revenue · Q1-2026 | $21.61B | +11% y/y |
| Gross Profit · Q1-2026 | $2.32B | -11% y/y |
| Operating Profit · Q1-2026 | $484M | -45% y/y |
| Net Income · Q1-2026 | $242M | -57% y/y |
| Gross Margin · Q1-2026 | 10.8% |
Risks flagged
Sharp earnings decline with margin compression; cost inflation outpacing revenue growth.
“Net income down 56.6% YoY; operating profit down 45.1%; gross margin down 260 bps.”
30 Apr 20266-KJBS N.V. held its 2026 Annual General Meeting; all agenda items adopted including annual accounts, director reappointments, and auditor reappointment. No material financial or operational changes disclosed.open
Figures in the filing · each found in the filing text
| Net Revenue · FY2025 | $86.00B | +12% y/y |
| Net Income · FY2025 | $2.00B | +13% y/y |
13 Apr 20266-KJBS N.V. announces tender offer results and upsized cap to US$1.2B, and US$500M re-tap of 2037 & 2057 notes. Net proceeds used for tender offer and general corporate purposes. No earnings or guidance.open
Figures in the filing · each found in the filing text
| aggregate principal amount of 2034 notes tendered · point_in_time | $1.32B | |
| aggregate principal amount of 2035 notes tendered · point_in_time | $830M | |
| increased maximum amount for tender · point_in_time | $1.20B | |
| additional 2037 notes principal · point_in_time | $250M | |
| additional 2057 notes principal · point_in_time | $250M |
Risks flagged
Increased debt may raise leverage; but refinancing extends maturities.
“Upsized tender cap and additional note issuances.”
31 Mar 20266-KJBS prices $2B senior notes offering: $1.25B at 5.625% due 2037 and $750M at 6.400% due 2057. Proceeds to fund tender offers for existing notes and general corporate purposes.open
Figures in the filing · each found in the filing text
| Notes Offering Amount · Q1-2026 | $2.00B |
Risks flagged
Debt refinancing risk reduced; leverage remains elevated but manageable with successful pricing.
“Net proceeds used to pay consideration for tender offers of up to $1B of existing notes and for general corporate purposes.”
26 Mar 20266-KJBS reports record sales in 4Q25 and FY2025, with net sales up 15% and 12% YoY respectively, but adjusted EBITDA declined 7% and 5% due to cattle cost pressure. Net income grew 1% and 15%.open
Figures in the filing · each found in the filing text
| Net Sales · Q4-2025 | $23.06B | +15% y/y |
| Net Sales · FY2025 | $86.18B | +12% y/y |
| Adjusted EBITDA (IFRS) · Q4-2025 | $1.72B | -7% y/y |
| Adjusted EBITDA (IFRS) · FY2025 | $6.83B | -5% y/y |
| Net Income Attributable to JBS · Q4-2025 | $415M | +1% y/y |
| Net Income Attributable to JBS · FY2025 | $2.02B | +15% y/y |
| Earnings Per Share · Q4-2025 | $0.39 | +1% y/y |
| Earnings Per Share · FY2025 | $1.89 | +15% y/y |
| Free Cash Flow · Q4-2025 | $990M | |
| Free Cash Flow · FY2025 | $400M |
Risks flagged
Cattle cost inflation and supply constraints pressuring beef margins.
“increase in cattle prices outpaced the change in cutout values, reflecting tighter cattle availability amid the ongoing U.S. cattle cycle. In addition, live cattle imports from Mexico were restricted beginning in May 2025, further constraining supply in the U.S. market for much of the year.” · word for word
Temporary export restrictions due to avian influenza in Brazil.
“temporary restrictions in key markets such as China and Europe following a single avian influenza case in Brazil in May.” · word for word
25 Mar 202620-FAnnual report (20-F) filed by JBS N.V. for FY2025, containing standard debt and covenant disclosures, capex increase, and trend information.open
Figures in the filing · each found in the filing text
| Net Revenue · FY2025 | $86.18B | +12% y/y |
| Net Income · FY2025 | $2.23B | +13% y/y |
| Adjusted EBITDA · FY2025 | $6.83B | -5% y/y |
| Adjusted EBITDA Margin · FY2025 | 7.9% | |
| Total Outstanding Indebtedness · FY2025 | $21.09B | |
| Dividend per Share · FY2025 | $1.00 |
Risks flagged
Material Weakness in Internal Controls
“We identified a material weakness in our internal controls. ... relate to ineffective design, implementation and operation of general information technology controls, or GITCs, in the areas of user access and program change-management over certain information technology systems in certain of our subsidiaries that support our financial reporting processes.” · word for word
Avian Influenza Export Disruption
“In May 2025, a single case of avian influenza was recorded in Brazil, resulting in a temporary restriction of exports to key markets such as Europe and China, impacting the revenue of our chicken exports until September and November 2025, respectively.” · word for word
Controlling Shareholder Influence
“Our ultimate controlling shareholders held 85.68% of voting power as of March 18, 2026. This significant concentration of voting rights gives them substantial influence over our company.” · word for word
Beef North America Segment Losses
“Beef North America segment had net revenue of US$28.1 billion and Adjusted EBITDA of US$(319.5) million.” · word for word
High Indebtedness
“As of December 31, 2025, our total outstanding indebtedness was US$21,090.6 million” · word for word
9 Feb 20266-KJBS invests USD 150M in joint venture in Oman to establish a multiprotein hub, holding 80% stake; capacity ~300k tons/year.acquisitionopen
Figures in the filing · each found in the filing text
| Investment amount | $150M | |
| Enterprise Value pre-money | $168M | |
| Production capacity | $300000.00 |
Risks flagged
Execution risk in establishing operations in Oman and obtaining regulatory approvals
“Consummation subject to regulatory approvals; production start within 6-12 months.”
25 Nov 20256-KJBS enters binding MOU to form JBS VIVA, a 50/50 JV with VIVA shareholders combining leather assets; JBS VIVA will process >20M hides/year with 31 factories.being acquiredopen
Figures in the filing · each found in the filing text
| hides processed per year · leather · unknown | 20,000,000 | |
| number of factories · leather · unknown | 31 | |
| number of employees · leather · unknown | 11,000 |
Risks flagged
Transaction completion risk: subject to definitive documents and conditions precedent.
“The completion of the transaction is subject to the negotiation of definitive documents and other conditions precedent common to this type of transaction.” · word for word
Integration and operational risks from combining two companies' leather operations across multiple countries.
“unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies” · word for word
21 Nov 20256-KJBS N.V. becomes successor co-issuer of 15 series of notes (total ~$15B) and borrower under revolving credit facility; JBS S.A. released as guarantor. Financial covenant changed from max debt-to-capitalization 55% to min interest coverage ropen
Figures in the filing · each found in the filing text
| minimum interest coverage ratio · Q2-2026 | $3.00 |
Risks flagged
Debt covenant change reduces balance sheet risk; interest coverage test is more flexible than leverage test.
“Replaced max debt to capitalization (55%) with min interest coverage (3.00x).”
13 Nov 20256-KJBS N.V. reported Q3 2025 net revenue of $63.1B (9M) vs $57.2B prior year, net income $1.79B vs $1.51B; operating profit $3.21B vs $3.41B; strong revenue growth but slight operating margin compression.open
Figures in the filing · each found in the filing text
| Net Revenue · 9M-2025 | $63.12B | +10% y/y |
| Net Income · 9M-2025 | $1.79B | +19% y/y |
| Gross Profit · 9M-2025 | $8.43B | -2% y/y |
| Operating Profit · 9M-2025 | $3.21B | -6% y/y |
Risks flagged
Gross margin pressure from input cost inflation
“Gross profit declined despite revenue growth; cost of sales increased to $54.7B from $48.6B”
10 Nov 20256-KJBS concludes share repurchase program, repurchasing 41,008,292 shares for $600 million; efficient use of cash at comfortable leverage.open
Figures in the filing · each found in the filing text
| Share repurchase amount · consolidated · program period | $600M |
JBS N.V. — questions
- What did JBS N.V. file recently?
- 26 SEC filings in the last 12 months. Latest: 8-K on 2026-09-15 — JBS N.V. filed an 8-K with only Item 9.01 (financial statements and exhibits) and no substantive Item 8.01 disclosure. The filing contains only a cover page exhibit. No material event.
Every figure on this page comes from JBS N.V.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.